Shuwen Duan

Title: **Inventor Spotlight: Shuwen Duan**

Introduction

Shuwen Duan, a noted inventor based in Shanghai, China, has made significant contributions in the field of pharmaceuticals, particularly in the fight against breast cancer. With a focus on innovative compounds, his research and developments are aimed at improving therapeutic strategies for estrogen receptor-positive breast cancer treatment.

Latest Patents

Shuwen Duan holds a patent for an essential compound known as an estrogen receptor antagonist. This invention specifically relates to an indole compound represented by formula (II) and includes its isomers or pharmaceutically acceptable salts. The patent emphasizes the compound's utility in formulating drugs designed to treat estrogen receptor-positive breast cancer, showcasing the potential impact of his work in the medical field.

Career Highlights

Duan is associated with Chia Tai Tianqing Pharmaceutical Group Co., Ltd., a prominent company focused on advancing pharmaceutical solutions. His work has contributed significantly to the development of effective treatments, reflecting his dedication to addressing critical health issues. With one key patent to his name, Shuwen has established himself as an inventor capable of driving innovation in healthcare.

Collaborations

Throughout his career, Shuwen Duan has collaborated with talented colleagues, including Jianyu Lu and Lihong Hu. These partnerships highlight the collaborative efforts that often enhance creative problem-solving and lead to breakthroughs in the pharmaceutical industry.

Conclusion

Shuwen Duan's contributions as an inventor in the pharmaceutical sector underscore the vital role of innovation in addressing medical challenges. His work on estrogen receptor antagonists has the potential to influence treatment protocols for breast cancer, demonstrating the importance of ongoing research and development in improving patient outcomes. As he continues to advance his career, his influence in the field is anticipated to grow further.